Clinical trial · Observational
Observational Study of Biomarker During Liver Surgery
Autophagy in Liver Injury: Changes in Autophagy Biomarkers During Liver Surgery
NCT02102971CI-TRIAL-00040823terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Expired with UF IRB.
Summary
Brief summary (as posted)
The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver diseases.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatobiliary Tract Adenomas and Carcinomas | — | UNRESOLVED | — |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hepatocellular carcinoma | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hepatocellular carcinoma
- description
- Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
- interventionNames
- Procedure: Hepatocellular carcinoma
Primary outcomes (1)
- measure
- Biochemical analysis of sirtuin1 from liver tissues during liver surgery
- timeFrame
- 30 minutes during liver surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * liver resection \> 2 segments, * plate count \> 100 x 109/L, and * prothrombin activity \>60%. Exclusion Criteria: * liver cirrhosis, * portal hypertension, * steatohepatitis or severe steatosis, * patients receiving additional ablation therapies, * laparoscopic resection, and * simultaneous extrahepatic procedures such as colorectal resection or pancreatoduodenectomy
References
Publications (0)
Data not yet available
No reference posted for this study.